Omega Therapeutics Inc
NASDAQ:OMGA
Omega Therapeutics Inc
NASDAQ:OMGA
Price:
2.355 USD
20.15%
Market Closed
Updated:
May 14, 2024
P/E
Price to Earnings
Price to Earnings
-1.3
Current
-2.7
Median
27.4
Industry
Higher
than median
Lower
than industry value
Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.
P/E
=-1.3
Market Cap
/
129.9m
Net Income
-97.4m
All Countries
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| US |
|
Omega Therapeutics Inc
NASDAQ:OMGA
|
129.9m USD | -1.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
284.8B USD | 59.1 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
165.5B USD | 44 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110.8B USD | 30.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
107.7B USD | 27.9 | |
| AU |
|
CSL Ltd
ASX:CSL
|
135.2B AUD | 36.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
84.2B USD | 173.9 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
48.1B USD | -8.1 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | -57.5 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
32.8B USD | 28.1 | |
| KR |
|
Celltrion Inc
KRX:068270
|
39.5T KRW | 73.8 |
P/E Forward Multiples
Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
P/E
-2
2-Years Forward
P/E
-1.9
3-Years Forward
P/E
-2.9
You don't have any saved screeners yet
